Rational design of potent, bioavailable, nonpeptide cyclic ureas as HIV protease inhibitors.

Department of Virology Research, DuPont Merck Pharmaceutical Company, Wilmington, DE 19880.

Mechanistic information and structure-based design methods have been used to design a series of nonpeptide cyclic ureas that are potent inhibitors of human immunodeficiency virus (HIV) protease and HIV replication. A fundamental feature of these inhibitors is the cyclic urea carbonyl oxygen that mimics the hydrogen-bonding features of a key structural water molecule. The success of the design in both displacing and mimicking the structural water molecule was confirmed by x-ray crystallographic studies. Highly selective, preorganized inhibitors with relatively low molecular weight and high oral bioavailability were synthesized.

PMID: 8278812 [PubMed - indexed for MEDLINE]